Pace Nicholas J
Known title: EVP General Counsel & CorpSecCIK: 0001497051
Associated companies
Transaction History
| ACH | ▼ Sell | Tax Withholding | 4,947 | $93K | 5/15/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 7,186 | $132K | 5/11/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 32,878 | $429K | 3/15/2023 | View on chart |
| ACH | ▲ Buy | Grant | 42,099 | $0 | 3/1/2023 | View on chart |
| ACH | ▲ Buy | Grant | 35,150 | $0 | 3/1/2023 | View on chart |
| ACH | ▲ Buy | Grant | 32 | $529 | 12/30/2022 | View on chart |
| ACH | ▲ Buy | Grant | 551 | $15K | 6/30/2022 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 2,695 | $97K | 5/16/2022 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 7,185 | $270K | 5/11/2022 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 61,184 | $2.6M | 3/4/2022 | View on chart |
| ACH | ▲ Buy | Grant | 15,198 | $0 | 3/3/2022 | View on chart |
| ACH | ▲ Buy | Grant | 96,552 | $0 | 2/9/2022 | View on chart |
| ACH | ▼ Sell | Open Market | 2,400 | $102K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 643 | $29K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 100 | $5K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 5,267 | $218K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 600 | $26K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 1,900 | $86K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 1,153 | $47K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 17,956 | $745K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 13,639 | $581K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 3,318 | $145K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 2,394 | $108K | 11/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice
Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.